http://www.craneware.com/

Craneware, Inc. is a leading supplier of business intelligence and revenue cycle software that provides clients with chargemaster management software and products designed to optimize legitimate reimbursements and assist in managing the revenue cycle through better information, workflow, pricing strategy, capture of lost revenue and best practice modeling. Our innovative and scalable products are designed to ensure that you have the information you need to succeed in healthcare financial management.

A talented mix of employees from the healthcare industry, software engineering, business consulting, customer support and training provide the perfect blend for providing extremely powerful solutions to problems faced by hospital's financial teams.

Our consultant's years of experience in the healthcare industry are the vital source of financial, clinical and coding expertise that together with talented software developers combine to make our products so effective.

Our dedicated support team work hard at ensuring our customers always come first and pride themselves on exemplary service throughout the relationship from first install to advanced user training. Installation times are in weeks instead of months, Support responses are in minutes instead of days.

Headquartered in Scotland with offices across the US, Craneware delivers unparalleled solutions to the problems facing healthcare financial managers every day.

Trading Update, Contract Win and Notice of Results

RNS


RNS Number : 3413D

Craneware plc

06 July 2016




Craneware plc

("Craneware", "the Group" or the "Company")



Trading Update, Significant Contract win and Notice of Results



6 July 2016 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the year ended 30 June 2016.



The Board is pleased to confirm the Group's third consecutive year of record sales performance and a return to double digit growth at the revenue and adjusted EBITDA level.



The Group has seen greater than 60% growth in the value of 'New Sales' contracts signed of c$58m (2015 $35.9m) with the average new contract length being maintained at 5 years.



Included in the year's sales success are two significant contracts. The first announced on 2 February 2016 was for a 50 hospital group in excess of $7.5m revenue over its five year life. In addition to this the Company is pleased to announce that it finished the year with a further multi-hospital group contract win. Starting in FY17, the contract is expected to deliver revenue greater than $8m during the next five years, as the hospital network rolls out multiple Craneware core value cycle solutions.



In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from all sales will be recognised over future periods, adding to the Group's long term visibility of revenue under contract. Accordingly the Group expects to report an increase of 11% in revenues and 10% in adjusted EBITDA for the year ended 30 June 2016.



Other key performance indicators continue to be positive. The Group continued to renew hospitals that were due for renewal in the year at an average of above 100% (by $ value) and customer retention continues to be significantly higher than the industry norm.



Strong cash generation resulted in cash reserves in excess of $47m at 30 June 2016 (2015 $41.8m).



Keith Neilson, CEO of Craneware plc commented, "US Healthcare providers continue to address the challenges the new value based re-imbursement environment brings. We believe our continued sales growth demonstrates the strategic importance of Craneware and its Value Cycle solutions to them as they meet these challenges. The ongoing investment we are making to develop solutions that discover, convert and optimise value for healthcare providers, combined with our own historical sales successes, double digit revenue and adjusted EBITDA growth, give management confidence in its ability to deliver continued future growth as well as increasing stakeholder value."



The Company will announce its Full Year Results on 6 September 2016.

6 Jul Peel Hunt 920.00 Buy

Craneware PLC (CRW:LSE) set a new 52-week high during Wednesday's trading session when it reached 895.00. Over this period, the share price is up 44.44%.

25 Aug Peel Hunt 1,335.00 Buy

Final Results

RNS


RNS Number : 0121J

Craneware plc

06 September 2016




Craneware plc

("Craneware", "the Group" or the "Company")

Final Results



6 September 2016 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its results for the year ended 30 June 2016.



Financial Highlights (US dollars)
•Total Contract Value in the year continues at record levels of $82.3m (FY15: $72.9m) ◦new sales increased by 63% to $58.6m (FY15: $35.9m)
◦renewal rate remains above 100% by dollar value

•Revenue increased 11% to $49.8m (FY15: $44.8m)
•Adjusted EBITDA1. increased by 10% to $15.9m (FY15: $14.4m)
•Profit before tax increased by 10% to $13.9m (FY15: $12.5m)
•Basic adjusted EPS increased 13% to $0.429 (FY15: $0.378) and adjusted diluted EPS has increased to $0.423 (FY15: $0.375)
•Continued operating cash conversion above 100% of Adjusted EBITDA
•Cash at year-end of $48.8m (FY15: $41.8m) after payment of $6m dividend to shareholders
•Proposed final dividend of 9p (12 cents) per share giving a total dividend for the year of 16.5p (22 cents) per share (FY15: 14p (22 cents) per share)



1. Adjusted EBITDA refers to earnings before acquisition and share related transaction costs, interest, tax, depreciation, amortisation and share based payments.





Operational Highlights (Finals)
•US healthcare market continues its evolution towards value-based care with a critical dependency on accurate financial and operating data
•Further expansion of the product suite to support the Value Cycle, including: ◦development of Trisus Patient Payment Module, our Patient Engagement and Access gateway product, on track for launch during calendar 2016
◦launch of Craneware Healthcare Intelligence, a new group business, developing new solutions to address an emerging but significant market opportunity for healthcare cost analytics

•Two significant 5 year contract wins in the year for Craneware core value cycle solutions, worth a combined $15.5m
•Continued very high levels of customer retention
•Total visible revenue increased 23% to $149.1m (FY15 same 3 year period: $121.1m)



Keith Neilson, CEO of Craneware plc commented, "Craneware is in a stronger position than ever and we are passionate about the opportunity ahead. The double digit growth in our reported revenue and adjusted EBITDA are only beginning to reflect the record levels of sales which began three years ago. Importantly, the investment we are making in our product suite mean our market opportunity is now several times larger than it was when we joined AIM in 2007.



"The market continues to evolve as we anticipated. US healthcare providers are seeking the solutions to address the challenges the new value based re-imbursement environment brings to them. We believe the investment we are making to expand the products in our Value Cycle suite addresses these challenges and we are now recognised beyond our original niche within the revenue cycle as a more strategic provider within a hospital's financial operations and their value cycle.



"We are confident that the ongoing investment we are making, combined with our continuing sales successes, mean we are well positioned to deliver continued future growth as well as increasing stakeholder value."

New high.

Director/PDMR Shareholding
RNS
RNS Number : 2394K
Craneware plc
20 September 2016
 
 
Craneware plc
("Craneware" or the "Company")
 
Director Shareholding
 
20 September 2016 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, has been informed that Keith Neilson, CEO of the Company, yesterday purchased 5,388 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 1,200 pence per share.
 
Following this transaction, Mr. Neilson's beneficial interest in Craneware has increased to 3,509,518 Ordinary Shares, representing approximately 13.1% of the Company's issued Ordinary Share capital.
 

AGM Statement
RNS
RNS Number : 5525O
Craneware plc
08 November 2016
 
Craneware plc
("Craneware", "the Group" or the "Company")
AGM Statement
 
8 November 2016 - Craneware plc (AIM: CRW.L), the leader in Value Cycle solutions for the US healthcare market, will be holding its Annual General Meeting today at 10am. At the meeting, Keith Neilson, CEO of the Company, will make the following statement:
 
"We continue to see positive results in the first few months of the current fiscal year. In September we announced the move back into double-digit revenue and adjusted EBITDA growth. With the impact of sales made during FY16 starting to contribute to revenue, combined with our sales pipeline and activity, we see that momentum continuing in the current year.
 
"The US healthcare market continues its evolution towards value-based care with a critical dependency on accurate financial and operating data. We are investing in our Value Cycle product suite to ensure we have the solutions to provide hospitals with tools that deliver insight into these areas of their operations, expanding our market opportunity and increasing our strategic value within our market.
 
"2017 will see some exciting developments for Craneware with the launch of Trisus Claims Informatics, the first product to be launched on our newly developed cloud-based Trisus Enterprise Value Platform; followed shortly thereafter by the launch of Trisus Patient Payment, a new fourth gateway product, operating within the patient access and engagement area. 
 
"We are also making good progress within our newly formed Group business, Craneware Healthcare Intelligence, which is focused on the development of cost analytics software for the US healthcare industry.
 
"With our expanded offering and market opportunity, high levels of revenue visibility and favourable market backdrop, we believe we are just at the start of a long-term growth trajectory and are confident in the future success of Craneware."
 

10 Nov
Peel Hunt
1,335.00
Buy

Trading Update
RNS
RNS Number : 2943U
Craneware plc
17 January 2017
 
Craneware plc
("Craneware", "the Group" or the "Company")
 
Trading Update
 
17 January 2017 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the six months ended 31 December 2016.
 
The Group is pleased to announce continued growth and expects to report 15% increases in both revenue and adjusted EBITDA for the six month period ended 31 December 2016, building on the return to double digit growth reported in the year to 30 June 2016 and slightly ahead of expectations.
 
Underlying sales continue to support this growth, with a particularly strong Q2, post the US Election result, and a healthy sales pipeline.  In accordance with the Company's revenue recognition policy the vast majority of revenue resulting from sales made in the period will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
 
The Group continues to invest for the future.  In the period it has invested c$3m in its newly formed Employee Benefit trust and over $1.0m in future product development, including its cloud-based Trisus product suite and the new Craneware Healthcare Intelligence product suite. 
 
The Group's cash balance at the end of the period was maintained at $45m (H116: $45m) after making these investments whilst continuing a progressive dividend payment policy. In addition, the Group retains an available funding facility from the Bank of Scotland of up to $50m as it continues to investigate strategic opportunities to further expand its Value Cycle solution. 
 
With the growth in the period, continued cash generation and a healthy sales pipeline, the Board is confident in meeting market expectations for the full year.
 
The Company will announce its results for the six months ended 31 December 2016 on 7 March 2017.
 
Keith Neilson, CEO of Craneware plc commented, "There is continued consensus in the US of the need to drive value in Healthcare with ongoing support for the move to value-based care and increasing consumerism. An impending change of government always brings with it an element of uncertainty, it was therefore particularly pleasing to see the acceleration in sales of our Value Cycle solutions post the result of the US Presidential election. Our Value Cycle software continues to help US Healthcare providers meet the challenges they will face as they navigate the ongoing re-imbursement model changes. 
 
"We continue to invest in both our current solutions and in the new products we are developing to expand our support to US Healthcare providers as they pursue quality patient outcomes and optimal financial performance.
 
"These supportive market drivers, our investment for the future and our continued profitable growth, give management confidence in its ability to deliver continued stakeholder value."
 

17 Jan
Peel Hunt
1,335.00
Buy

Half-year Report
RNS
RNS Number : 6750Y
Craneware plc
07 March 2017
 
Craneware plc
("Craneware", "the Group" or the "Company")
 
Interim Results
 
7 March 2017 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its unaudited results for the six months ended 31 December 2016.
 
Financial Highlights (US dollars)
Revenue increased 16% to $26.8m (H1 2016: $23.1m)
Adjusted EBITDA1 increased 16% to $8.2m (H1 2016: $7.1m)
Profit before tax increased 23% to $7.5m (H1 2016: $6.1m)
Adjusted basic EPS increased 15% to 21.6 cents per share (H1 2016: 18.8 cents per share)
Strong cash position maintained at $45m (H1 2016: $45m) following dividend payment of $3.2m and investments of $4.5m made during the period
Proposed interim dividend increased 16% to 8.7p (H1 2016: 7.5p per share)
 
1.   Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments and acquisition and share transaction related costs.
 
Operational Highlights
Consensus for the need to drive value in US Healthcare provides supportive market dynamics
Continued growth supported by underlying sales and sales pipelines
Expansion of the Value Cycle solution suite on track with initial components of the cloud-based Trisus Enterprise Value Platform being rolled out during the calendar year
Positive progress with Craneware Healthcare Intelligence, a new solution set developed to address the significant market opportunity for healthcare cost analytics
Total visible revenue of over $55.4m for the current year and $155.5m for the three year period to June 2019 (H1 2016 same three year period: $128.1m)
Board confident in outlook for the year
 
Keith Neilson, CEO of Craneware plc commented, "The first half of the year has been a period of successful execution against our stated growth strategy, delivering accelerated growth at both the revenue and adjusted EBITDA level. During the period we have taken significant strides forward in terms of delivering our expanded product suite, educating our market place and also further investing in our people.  These ongoing achievements mean we are well positioned to deliver against a market opportunity that is now considerably larger than at any other point in our history.
 
"Against a backdrop of the recent US Presidential election, the overriding consensus for the need to drive value in US Healthcare has been re-affirmed.  There is ongoing support for the move to value-based care and increasing consumerism. Our Value Cycle software suite will continue to help US Healthcare providers meet the challenges they will face as they navigate the ongoing re-imbursement model changes. 
 
"These supportive market drivers, our investment for the future and our continued profitable growth give us confidence in continuing to deliver value for our stakeholders."

7 Mar
Peel Hunt
1,450.00
Buy

Significant Contract Win
RNS
RNS Number : 2611A
Craneware plc
23 March 2017
 
Craneware plc
("Craneware", "the Group" or the "Company")
 
Significant Contract Win
 
23 March 2017 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce a significant new contract with a large hospital operator in the US.
 
This win, with an existing customer, adds further Value Cycle solutions and related services to a seven year contract originally announced in April 2014.  The contract is expected to deliver a further $3.7m of revenue over this new seven year term as the hospital network rolls out these additional solutions across its facilities and $1.5m of additional revenue as the contract for the currently implemented solutions is extended to run co-terminus to this amendment.
 
In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from this contract will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.
 
Keith Neilson, CEO of Craneware plc, commented, "The strategic importance of Craneware's Value Cycle solutions allow us to add new customers and deepen our relationship with our existing customers as both groups address the challenges resulting from the continued evolution to the new value based re-imbursement environment. The extension of the solution set provided to this customer and increasing the duration of the original contract underlines the value our solutions bring to our customers. We have a very positive relationship with our customers, demonstrating sustainable value; we now look forward to this extension of our working relationship with this customer to over a decade."

26 Apr
Peel Hunt
1,450.00
Buy

08:00 11/07/2017
Broker Forecast - Peel Hunt issues a broker note on Craneware PLC
Peel Hunt today reaffirms its buy investment rating on Craneware PLC (LON:CRW) and raised its price target to 1495p (from 1450p). Story provided by StockMarketWire.com

Final Results
RNS
RNS Number : 7912P
Craneware plc
05 September 2017
 
Craneware plc
("Craneware", "the Group" or the "Company")
Final Results
Double digit revenue and profit growth and successful transition into execution phase of the growth strategy
 
5 September 2017 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its results for the year ended 30 June 2017.
 
Financial Highlights (US dollars)
·      Revenue increased 16% to $57.8m (FY16: $49.8m)
·      Adjusted EBITDA1.  increased 13% to $18.0m (FY16: $15.9m)
·      Profit before tax increased 22% to $16.9m (FY16:  $13.9m)
·      Basic adjusted EPS increased 20% to $0.514 (FY16:  $0.429) and adjusted diluted EPS increased to $0.503 (FY16: $0.423)
·      Total visible revenue increased 13% to $163.8m (FY16 same 3 year period: $145.3m)
·      Continued operating cash conversion above 100% of Adjusted EBITDA
·      Cash at year-end of $53.2m (FY16: $48.8m) after payment of $6.4m dividend to shareholders and increased investment of over $3.0m in R&D
·      Proposed final dividend of 11.3p (14.71 cents) per share giving a total dividend for the year of 20.0p (26.04 cents) per share (FY16: 16.5p (22 cents) per share)
·      Renewal rate remains above 100% by dollar value
 
1.  Adjusted EBITDA refers to earnings before acquisition and share related transaction costs, interest, tax, depreciation, amortisation and share based payments.
 
Operational Highlights
·      Continued supportive market environment as the US healthcare market evolves towards value-based care, with a critical dependency on accurate financial and operating data
·      Continued high levels of customer acquisition and retention
·      Successful launch of cloud-based Trisus™ platform, with extremely positive customer response
·      Initial sales of Trisus Claims Informatics™, the first product on the Trisus™ platform
·      Early adopters secured for Craneware Healthcare Intelligence, the Group's new business focused on healthcare Cost Analytics and Resource Efficiency (CARE)
·      Record sales pipeline for the current financial year
 
Keith Neilson, CEO of Craneware plc commented, "We are delighted to report that, with record levels of revenue and profitability, the launch of our Trisus platform with secured sales for the first Trisus product (Trisus Claims Informatics™), and the launch of Craneware Healthcare Intelligence, this was the year in which we saw our unique vision of the Value Cycle, turn from concept to reality.
 
"While laying out our vision for the Value Cycle over the last two years, Craneware has delivered double digit growth in our key metrics, including revenue and profit, supported by sales success throughout the period. We have expanded our product suite into the Value Cycle; developed a new cloud-based technology platform, Trisus; and created a new Group business, Craneware Healthcare Intelligence, all significantly increasing the Company's total addressable market. At the same time we have been investing in improving our customers' experience and have returned in excess of $15m to shareholders by way of dividends and share buy backs.
 
"The unceasing evolution of the US healthcare market towards value-based care presents us with an ongoing, growing market opportunity and the investments we have made mean we now have the potential to deliver against this expanding opportunity. With our sales pipeline increasing each year, this increased scalability and opportunity, combined with our high levels of revenue visibility, strong cash position and extensive customer base provide us with confidence in Craneware's ongoing success."

5 Sep
Peel Hunt
1,495.00
Buy

Anyone subscribing to the MoneyAM Level 2 platform please take note that most days it is not reporting the correct Trade High nor Trade Low information and "some days" not reporting the correct Opening Price or Closing Price.

The reason is because MoneyAM's Level 2 system is not correctly sensing the Auto Trades or Ordinary Trades correctly so is wrongly reporting them

Craneware shareholders approve 11.3p final divi
StockMarketWire.com
Craneware has confirmed that shareholders approved the proposed final dividend of 11.3p per share at today's Annual General Meeting, taking the total dividend for the year to 20p.

The final dividend will be paid on 7 December to shareholders on the register as at 10 November, with a corresponding ex-Dividend date of 9 November.



At 1:14pm: (LON:CRW) Craneware PLC share price was +10p at 1325p


Story provided by StockMarketWire.com